Core Insights - Dyne Therapeutics presented new preclinical data for DYNE-302, demonstrating robust and durable DUX4 suppression and functional benefits in models of facioscapulohumeral muscular dystrophy (FSHD) [1][7] - The data were showcased at the 31st Annual FSHD Society International Research Congress, indicating the potential of DYNE-302 as a therapeutic candidate for FSHD, a disease with no currently approved therapies [1][7] Company Overview - Dyne Therapeutics is a clinical-stage company focused on developing innovative therapeutics for genetically driven muscle diseases, utilizing its proprietary FORCE™ platform [12] - The FORCE platform is designed to enhance the delivery of oligonucleotide therapeutics to muscle tissue, addressing limitations in current treatment approaches [11][12] Product Candidate Details - DYNE-302 targets the genetic cause of FSHD by utilizing a fragment antibody that binds to transferrin receptor 1 (TfR1), conjugated with siRNA to reduce DUX4 expression [8][10] - In preclinical studies, a single intravenous dose of DYNE-302 resulted in a dose-dependent reduction of the DUX4 transcriptome lasting up to three months, with observed benefits on muscle structure and function [1][7] Disease Context - FSHD is a severe muscle disorder caused by aberrant expression of the DUX4 gene, leading to progressive muscle loss and weakness, affecting an estimated 16,000-38,000 individuals in the U.S. and approximately 35,000 in Europe [10] - There are currently no approved therapies for FSHD, highlighting the significant unmet medical need in this area [10]

About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life- transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystr ...

Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could DYN face a similar situation as it did in 2021 and 2023 and underperform the S&P over the next 12 months — or will it see a strong jump? The $39 average of analysts' price estimate reflects a little over 10% upside from its current levels of $35. Note that Dyne doesn't have any marketable product yet, and its valuation is purely based on its pipeline potential. Moreover, smaller pharmaceutical firms ...

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," ...

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering ex ...

Dyne Therapeutics (DYN) reported new clinical efficacy data from two separate mid to late-stage studies evaluating its two clinical-stage pipeline candidates, DYNE-101 and DYNE-251, in patients with myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping, respectively. New clinical data from both studies demonstrated a meaningful impact on key biomarkers and functional improvement in multiple clinical endpoints that matter to patients. We remind the investo ...

About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life- transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystr ...

Contacts: Investors About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life- transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duc ...

Top-notch biotech stock Dyne Therapeutics (DYN) broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy treatments. Dyne stock catapulted 22.4% to 33.89. Shares hit a record high, topping a buy point at 30.27 out of a consolidation, according to MarketSurge. The biotech stock's relative strength line also launched to a new high. X Top 2% Biotech Stock Dyne studied drugs it calls DYNE-101 and DYNE-251 in patients with myotonic dystrophy type 1 and Duchenne muscular ...

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon ...